MaxWell Biomedical

Managing Atrial Fibrillation (AF) and Heart Failure (HF) together requires a holistic approach:
1) Restoring sinus rhythm and 2) Preserving a healthy, functioning left atrium. Both are critical for improving outcomes in this challenging patient population.

AF and HF frequently coexist, with each condition worsening the other’s progression. Together, they significantly increase risks of stroke, dementia, HF hospitalization, and all-cause mortality, creating a major unmet need in cardiovascular care.

Maxwell Biomedical is transforming the treatment landscape with Rhythm360 Therapy—the first non-ablative (destructive) AF therapy and heart failure monitoring system specifically designed to address the unique needs of patients with both AF and HF. This groundbreaking innovation offers a safer, more effective solution for managing these interconnected conditions.

  • MaxWell Biomedical, a leader in cardiac care innovation, is excited to announce a significant milestone: the receipt of a $1.86 million grant from the National Institutes of Health (NIH), complemented by investments from private investors.

    This funding will accelerate the development of the MaxWell Biomedical Spatial Resynchronization Therapy (SRT) System, an innovative non-ablative technology designed to restore and maintain Functional Sinus Rhythm in patients with atrial fibrillation (AF).

    AF, a condition linked to severe complications such as stroke and heart failure, results in over 450,000 hospitalizations and approximately 160,000 deaths annually in the U.S. The MaxWell SRT System employs cutting-edge ultra-low energy stimulation to non-ablatively terminate AF, restoring left atrial function, without the discomfort associated with traditional high-energy cardioversion.
    Early trials have demonstrated the system's efficacy, with an impressive 83.3% success rate within 15 seconds and 100% success within 5-10 minutes.
    The SRT System is set to revolutionize cardiovascular care.

    Successfully executing the NIH SBIR Phase II award will position the SRT System for Investigational Device Exemption (IDE) approval, paving the way for the clinical studies needed to secure Pre-Market Approval (PMA) for this transformative technology aimed at treating the growing population of patients with AF and heart failure.

Revolutionizing AF and HF Care with Rhythm360 Therapy

At MaxWell Biomedical, we’re redefining the treatment of atrial fibrillation (AF) and heart failure (HF) with Rhythm360 Therapy, a groundbreaking, non-ablative (destruction) approach designed for patients facing the challenges of both conditions.

Our innovative Spatial Resynchronization Therapy (SRT) leverages advanced technology to restore sinus rhythm (SR) and preserve left atrial function (LAF) without damaging heart tissue. Rhythm360 Therapy operates through three transformative modes:

  • Preemptive Prevention: Proactively prevents AF by detecting early warning signs and delivering targeted pacing to stop episodes before they start.

  • Postemptive Termination: Seamlessly and imperceptibly terminates AF episodes, restoring sinus rhythm with precision and comfort.

  • Restorative Cardioversion: In rare cases of persistent AF, the system escalates to low-energy, pain-free cardioversion to ensure effective rhythm restoration.

Designed with patients in mind, Rhythm360 Therapy addresses the unmet needs of those with severe, coexisting AF and HF, offering a safer and more effective path to improved outcomes and quality of life. MaxWell Biomedical is leading the charge in transforming cardiac care.

At the core of MaxWell’s solution is a sophisticated three-stage approach that redefines AF management (Rhythm360 Therapy)

Active Atrial Fibrillation Management

Device Approach Designed to Address AF History

Maximum Wellness

[ mak-suh-muhm ] [ wel-nis ]